Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 953-961 , November 2006

Synthesis and biological evaluation of potent αvβ3-integrin receptor antagonists

  • Ingrid Dijkgraaf

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: +31 24 3619097; fax: +31 24 3618942.
    • ,
  • John A.W. Kruijtzer

      Affiliations

    • Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    • ,
  • Cathelijne Frielink

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Annemieke C. Soede

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Hans W. Hilbers

      Affiliations

    • Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    • ,
  • Wim J.G. Oyen

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Frans H.M. Corstens

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    • ,
  • Rob M.J. Liskamp

      Affiliations

    • Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    • ,
  • Otto C. Boerman

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Received 2 June 2006 ,Revised 29 August 2006 ,Accepted 29 August 2006.

References 

  1. Ruoslathi E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491–497
  2. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–1508
  3. Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, et al. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation. 2001;103:1906–1911
  4. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J. 1994;8:504–512
  5. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alpha(v)beta(3) antagonist. J Clin Invest. 1999;103:47–54
  6. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci. 1998;54:541–548
  7. Eliceiri BP, Cheresh DA. The role of alpha(v) integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227–1230
  8. Smith JW, Cheresh DA. The Arg–Gly–Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61–203 of the β subunit. J Biol Chem. 1988;263:18726–18731
  9. Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl. 1997;36:1374–1389
  10. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg–Gly–Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991;291:50–54
  11. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RDG peptides. Eur J Biochem. 1992;210:911–921
  12. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061–1071
  13. Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr3-octreotide by conjugation with carbohydrates. Bioconjug Chem. 2002;13:1021–1030
  14. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61–69
  15. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PloS Med. 2005;2:e70
  16. de Haan EC, Wauben MHM, Grosfeld-Stulemeyer MC, Kruijtzer JAW, Liskamp RMJ, Moret EE. Major histocompatibility complex class II binding characteristics of peptoid–peptide hybrids. Bioorg Med Chem. 2002;10:1939–1945
  17. Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J Med Chem. 1999;42:3033–3040
  18. Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, Banville S, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A. 1992;89:9367–9371
  19. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404–2407
  20. Kruijtzer JAW, Hofmeyer LJF, Heerma W, Versluis C, Liskamp RMJ. Solid-phase synthesis of peptoids using Fmoc-protected N-substituted glycines: the synthesis of (retro)peptoids of Leu-enkephalin and substance P. Chem Eur J. 1998;4:1570–1580
  21. Sieber P. An improved method for anchoring of 9-fluorenylmethoxycarbonyl-amino acids to 4-alkoxybenzyl alcohol resins. Tetrahedron Lett. 1987;28:6147–6150
  22. Applied Biosystems model 433A peptide synthesizers user's manual, Version 1.0, 1993.
  23. Applied Biosystems model 433A peptide synthesizer research news, June 1993, 1–12.
  24. Brouwer AJ, Monnee MCF, Liskamp RMJ. An efficient synthesis of N-protected beta-aminoethanesulfonyl chlorides: versatile building blocks for the synthesis of oligopeptidosulfonamides. Synthesis. 2002;11:1579–1584
  25. Janssen M, Frielink C, Dijkgraaf I, Oyen W, Edwards DS, Rajopadhye M, et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm. 2004;19:399–404
  26. Cheng HC. The power issue: determination of KB or Ki from IC50. A closer look at the Cheng–Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol Methods. 2002;46:61–71
  27. Cheng HC. The influence of cooperativity on the determination of dissociation constants: examination of the Cheng–Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations. Pharmacol Res. 2004;50:21–40
  28. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg–Gly–Asp ligand. Science. 2002;296:151–155
  29. Max R, Gerritsen RRCM, Nooijen PTGA, Goodman SL, Sutter A, Keilholz U, et al. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 1997;71:320–324
  30. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41–49
  31. Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11–19
  32. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. PEGylated Arg–Gly–Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med. 2004;45:1776–1783

PII: S0969-8051(06)00163-6

doi: 10.1016/j.nucmedbio.2006.08.008

Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 953-961 , November 2006

Article Tools

* Image Usage & Resolution